West Pharmaceutical Services (NYSE:WST) Updates FY 2025 Earnings Guidance

West Pharmaceutical Services (NYSE:WST) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 7.060-7.110 for the period, compared to the consensus earnings per share estimate of 6.760. The company issued revenue guidance of $3.1 billion-$3.1 billion, compared to the consensus revenue estimate of $3.0 billion.

West Pharmaceutical Services Stock Down 0.9%

WST stock opened at $276.87 on Thursday. The company has a current ratio of 2.78, a quick ratio of 2.08 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services has a twelve month low of $187.43 and a twelve month high of $352.33. The company’s 50 day moving average is $257.04 and its two-hundred day moving average is $232.65. The stock has a market cap of $19.91 billion, a P/E ratio of 41.45, a PEG ratio of 4.90 and a beta of 1.07.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings data on Thursday, July 24th. The medical instruments supplier reported $1.84 earnings per share for the quarter, topping analysts’ consensus estimates of $1.51 by $0.33. West Pharmaceutical Services had a net margin of 16.48% and a return on equity of 18.43%. The company had revenue of $766.50 million for the quarter, compared to analysts’ expectations of $725.11 million. During the same quarter last year, the company earned $1.52 earnings per share. The firm’s revenue for the quarter was up 9.2% on a year-over-year basis. Research analysts expect that West Pharmaceutical Services will post 6.62 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Zacks Research cut shares of West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 23rd. UBS Group lifted their target price on shares of West Pharmaceutical Services from $285.00 to $320.00 and gave the company a “buy” rating in a report on Friday, July 25th. Redburn Partners set a $311.00 price objective on West Pharmaceutical Services in a research note on Monday, September 15th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of West Pharmaceutical Services in a research note on Tuesday, October 14th. Finally, Evercore ISI set a $350.00 price objective on West Pharmaceutical Services in a research note on Tuesday, October 7th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $321.89.

Institutional Investors Weigh In On West Pharmaceutical Services

A number of institutional investors and hedge funds have recently modified their holdings of WST. CYBER HORNET ETFs LLC acquired a new stake in shares of West Pharmaceutical Services in the 2nd quarter worth approximately $25,000. MUFG Securities EMEA plc acquired a new stake in shares of West Pharmaceutical Services in the 2nd quarter worth approximately $47,000. State of Wyoming purchased a new stake in shares of West Pharmaceutical Services in the 2nd quarter worth about $49,000. Darwin Wealth Management LLC purchased a new stake in shares of West Pharmaceutical Services in the 2nd quarter worth about $75,000. Finally, EverSource Wealth Advisors LLC boosted its position in shares of West Pharmaceutical Services by 78.2% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 449 shares of the medical instruments supplier’s stock worth $98,000 after buying an additional 197 shares in the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.